Printer Friendly

COCENSYS ANNOUNCES MANAGEMENT ADDITIONS AND PROMOTIONS

     COCENSYS ANNOUNCES MANAGEMENT ADDITIONS AND PROMOTIONS
    IRVINE, Calif., Nov. 5 /PRNewswire/ -- CoCensys, Inc. today announced the appointment of Daniel L. Korpolinski to the positions of president and chief executive officer, effective Oct. 1, 1991.  Robert G. McNeil, Ph.D., former president and CEO, will maintain active involvement in the company as chairman of the board.  In addition, CoCensys announced that Kelvin W. Gee, Ph.D., has been promoted to chief scientific officer and that Donald W. Ashbrook, Ph.D., has been appointed vice president of scientific affairs.
    Korpolinski, 49, brings 27-years of senior management experience in the pharmaceutical industry to CoCensys.  Most recently, he held the position of president of Adria Laboratories, North America, from 1988 to 1991.  While at Adria, he was responsible for the strategic positioning of research and development, preclinical and clinical investigation, marketing and sales, licensing and corporate development programs.  As a result of Korpolinski's initiatives, the company formed a major partnership with Abbott Laboratories and significantly increased the number of Investigative New Drug (IND) and New Drug Approval (NDA) filings.  Previously, Korpolinski spent 24 years at the Upjohn Company, where he acquired extensive expertise in new product development and national sales and marketing, in addition to assessing and negotiating joint venture opportunities for the company.
    Dr. Ashbrook, 41, has 11 years of research and development experience in the pharmaceutical industry.  Prior to CoCensys, he served as vice president of clinical research and subsequently as vice president of scientific affairs for Sigma-Tau Pharmaceuticals, Inc. from 1988 to 1991.  He also served as vice president of clinical research for Chantal Pharmaceutical Corp. and held a variety of research positions at American McGaw.
    "Dan Korpolinski contributes valuable experience from leading U.S. pharmaceutical companies to our management team," said McNeil.  "Both Dan Korpolinski and Don Ashbrook will be instrumental in advancing CoCensys' novel receptor-based therapeutics for disorders such as epilepsy and anxiety through clinical trials and into the marketplace."
    McNeil, a co-founder of the company and former president and director, will now serve as chairman of the board.  Gee, also a co- founder of the company and former chief technical officer, will serve as chief scientific officer.
    CoCensys, Inc., founded in 1989, is a privately held biopharmaceutical company devoted to the identification of novel receptors and their complementary interacting ligands.  The company is currently developing its first novel class of compounds, known as Epalons, which target disorders of the CNS and brain.  Epalons interact with a specific receptor site that plays a key role in regulating and calming neuron activity and are being used in the diagnosis, treatment and prevention of behavioral disorders and neurological diseases.
    -0-           11/5/91
    /CONTACT:  Daniel L. Korpolinski, president and CEO of CoCensys, 714-727-2683, or Karen Bergman of Burns McClellan, 212-545-1919, for CoCensys/ CO:  CoCensys, Inc. ST:  California IN:  MTC SU:  PER PS -- NY004 -- 1074 11/05/91 08:01 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 5, 1991
Words:479
Previous Article:NEXT DOOR STORES STRESS TEAM APPROACH TO RECESSION, COMPETITION
Next Article:SOFTWARE TOOLWORKS RETURNS TO PROFITABILITY; THE COMPANY REPORTS NET INCOME OF $1.18 MILLION FOR ITS SECOND FISCAL QUARTER ENDED 9/30/91
Topics:


Related Articles
SOMERSET PHARMACEUTICALS SIGNS MARKETING AGREEMENT
COCENSYS REPORTS 1995 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
COCENSYS REPORTS FIRST QUARTER 1996 FINANCIAL RESULTS
COCENSYS ANNOUNCES SENIOR MANAGEMENT APPOINTMENTS
COCENSYS REPORTS SECOND QUARTER 1996 FINANCIAL RESULTS
CoCensys Names Vice President to Manage Clinical Data Internally
CoCensys to Market Zarontin to Neurologists for Parke-Davis
Watson Pharmaceuticals Acquires Neurology and Psychiatry Sales and Marketing Division From CoCensys, Inc.
CoCensys Sells Sales Division to Watson Pharmaceuticals
CoCensys Reports 1997 Fourth Quarter and Year End Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters